Isoniazid

Aka: Isoniazid, INH

advertisement

II. Indications

  1. Latent Tuberculosis Prophylaxis
  2. Multi-drug Tuberculosis Treatment Regimen

III. Contraindications

  1. G6PD Deficiency
  2. Severe hepatic insufficiency (reduce INH dose)
  3. Active hepatitis
  4. End-stage liver disease

IV. Mechanism

  1. Bactericidal agent interferes with formation of Mycobacteria cell walls (via mycolic acid synthesis blockade)
  2. Structurally similar to Pyridoxine

V. Medications

  1. Tablets: 100 and 300 mg
  2. Syrup: 50 mg/5 ml

VI. Dosing: Active Tuberculosis

  1. See Active Tuberculosis
  2. See Tuberculosis for specific dosing protocols and durations of treatment
  3. Tuberculosis treatment is a multi-drug regimen of which Isoniazid is a part
  4. Daily Dosing
    1. Adult: 5 mg/kg (up to 300 mg) orally or IM daily
    2. Child: 10 to 15 mg/kg (up to 300 mg) orally daily
  5. Intermittent Dosing
    1. Adult: 15 mg/kg (up to 900 mg) orally twice to three times weekly

VII. Dosing: Latent Tuberculosis

  1. See Latent Tuberculosis
  2. Daily Dosing
    1. Adult: 300 mg orally daily
    2. Child: 10 mg/kg (up to 300 mg) orally daily
  3. Intermittent Dosing (off label, but part of ATS guidelines)
    1. Use only for directly observed dosing, in non-HIV patients for adults (and children age>12 years)
    2. Isoniazid 15 mg/kg (up to 900 mg) once weekly AND
    3. Rifapentine

VIII. Adverse Effects: Hepatic

  1. Hepatotoxicity
    1. Subclinical Hepatitis: 10%
    2. Clinical Hepatitis: 1%
    3. Risk increases with age and Alcohol intake
  2. Progressive liver damage
    1. Under age 20 years: rare
    2. Age 30 to 50 years: 1.5%
    3. Age over 50 years: 2.5%
  3. Common presenting symptoms of drug-induced hepatotoxicity
    1. Nausea or Vomiting
    2. Abdominal Pain (>50% of patients)
    3. Fever (10%)
    4. Rash (5%)

IX. Adverse Effects: Neurologic

  1. Peripheral Neuropathy
    1. See prevention below
    2. Vitamin B6 (Pyridoxine) is important for Neurotransmitter synthesis (as well as Amino Acid synthesis)
      1. Isoniazid increases Pyridoxine urinary excretion and depletion, resulting in Peripheral Neuropathy
  2. Insomnia
  3. Restlessness
  4. Muscle Twitching
  5. Urinary Retention
  6. Seizures
  7. Psychosis
  8. Monoamine toxicity (MAO Inhibitor-like reaction)
    1. Presents with Flushing
    2. Avoid concurrent aged cheese and wine

X. Adverse Effects: Miscellaneous

  1. Lupus-Like Syndrome
  2. Hypersensitivity Reactions
    1. Hemolytic Anemia
    2. Stevens-Johnson Syndrome

XI. Prevention: Peripheral Neuropathy

  1. Indications for concurrent Vitamin B6 supplementation (Neuropathy risks)
    1. Pregnancy
    2. Breast Feeding infants
    3. Diabetes Mellitus
    4. Alcoholism
    5. Comorbid other Neuropathy
    6. Uremia
    7. Malnutrition
    8. HIV Infection
    9. Epilepsy
  2. Vitamin B6 (Pyridoxine)
    1. Pyridoxine 10 mg/day per 100 mg of INH
    2. Typical dose is 25-50 mg orally daily

XII. Drug Interactions

  1. Phenytoin (Dilantin)
    1. INH Increases blood level and toxicity
  2. Disulfiram (Antabuse)

XIII. Monitoring: Liver Function Tests

  1. Significant liver function abnormalities exceed 3-5 times normal with Isoniazid
    1. Stop Isoniazid if this occurs
  2. Baseline Liver Function Tests
    1. Controversial (some experts do not recommend baseline LFTs)
    2. Others recommend baseline testing and then monthly if abnormal baseline LFTs or if otherwise indicated (as below)
  3. Obtain monthly Liver Function Tests if:
    1. Abnormal baseline Liver Function Test
    2. Age >35 years
    3. History suggestive of Possible liver disorder
    4. Human Immunodeficiency Virus (HIV)
    5. Pregnancy
    6. Postpartum (within 3 months)
    7. Women who are bloack or hispanic
    8. Chronic Liver Disease
      1. Viral Hepatitis (Hepatitis B or Hepatitis C)
      2. Alcoholic Hepatitis
      3. Cirrhosis

XIV. Resources

  1. Isoniazid Tablet (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9499f1cf-2f46-4047-8b71-90aee7dee854

XV. References

  1. (2019) Presc Lett, Resource #350309, Tuberculosis Treatment in Adults: FAQ
  2. (2012) Med Lett Drugs Ther 10(116): 29-36
  3. (2000) MMWR Recomm Rep 49(RR-6): 1-51 [PubMed]

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Isoniazid." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Cost: Medications

isoniazid (on 8/23/2023 at Medicaid.Gov Survey of pharmacy drug pricing)
ISONIAZID 100 MG TABLET Generic $0.11 each
ISONIAZID 300 MG TABLET Generic $0.20 each
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information. GoodRx is another tool for finding lower drug prices.

Ontology: isoniazid (C0022209)

Definition (CHV) Antibacterial agent used primarily as a tuberculostatic
Definition (CHV) Antibacterial agent used primarily as a tuberculostatic
Definition (NCI) A synthetic derivative of nicotinic acid with anti-mycobacterial properties. Although its mechanism of action is still unclear, isoniazid appears to block the synthesis of mycolic acids, major components of the mycobacterial cell wall. This agent is only active against actively growing mycobacteria because, as a pro-drug, it requires activation in susceptible mycobacterial species. Isoniazid also interferes with mycobacterial metabolism of vitamin B6. Resistance occurs due to decreased bacterial wall penetration. (NCI04)
Definition (MSH) Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Definition (CSP) antibacterial agent used primarily as a tuberculostatic.
Definition (PDQ) A synthetic derivative of nicotinic acid with anti-mycobacterial properties. Although its mechanism of action is still unclear, isoniazid appears to block the synthesis of mycolic acids, major components of the mycobacterial cell wall. This agent is only active against actively growing mycobacteria because, as a pro-drug, it requires activation in susceptible mycobacterial species. Isoniazid also interferes with mycobacterial metabolism of vitamin B6. Resistance occurs due to decreased bacterial wall penetration. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39484&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39484&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C600" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D007538
SnomedCT 387472004, 81335000
LNC LP15831-8, MTHU008094
English Hydrazide, Isonicotinic Acid, Isoniazid, Isonicotinic Acid Hydrazide, 4-Pyridinecarboxylic acid, hydrazide, isonicotinyl hydrazine, isonicotinic acid hydrazide, Isonicotinyl Hydrazine, isoniazid (medication), ISONIAZID, Isoniazid [Chemical/Ingredient], inh, INA - Isoniazid, INAH - Isoniazid, INH, Isonicotinic acid hydrazide, Isonicotinylhydrazide, Isoniazid (product), Isoniazid (substance), isoniazid
Swedish Isoniazid
Czech isoniazid
Finnish Isoniatsidi
Russian IZONIAZID, IZONIKOTINOVOI KISLOTY GIDRAZID, ИЗОНИАЗИД, ИЗОНИКОТИНОВОЙ КИСЛОТЫ ГИДРАЗИД
Japanese イソニアジド, ピリジン-4-カルボヒドラジド, イソニコチン酸ヒドラジド
Spanish Isoniazida, Hidrazida del Ácido Isonicotínico, Hidracida del Ácido Isonicotínico, Isoniacida, isoniacida (sustancia), isoniacida, isoniazida (producto), isoniazida (sustancia), isoniazida, isonicotinilhidrazina, ácido isonicotínco hidrazina
Polish Izoniazyd, Hydrazyd kwasu izonikotynowego
French Isoniazide
German Isoniazid, Isonicotinsäurehydrazid
Italian Isoniazide
Portuguese Hidrazida do Ácido Isonicotínico, Isoniazida
Derived from the NIH UMLS (Unified Medical Language System)

Related Topics in Pharmacology

advertisement

2025 Family Practice Notebook, LLC. Terms | Privacy | About | Site Map | Newsletter | Blog

Footer Site Logo